MARKETS / BALCAO / LGMK
BALCAO · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

LogicMark, Inc. LGMK

14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$11.4M
▲ 15.4% vs FY2024
EPS · FY25
$-13.06
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-56.0%
Net margin · FY25
-65.4%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 11.4M
Revenue, FY2025 · full 14-year series below
Revenue Net income
0.0050.010.0150.020.0-0.0201220152018202120242025
0.0050.010.0150.020.0-0.02016201920222025

The company lost 65 cents on every revenue dollar this year.

Per share
USD -13.06
Diluted EPS, FY2025
EPS
0.40.81.2-13.06201220152018202120242025
0.40.81.2-13.062016201920222025

The company pays no cash dividend.

Profitability
-56.0%
Return on equity, FY2025
ROE
0.250.50.751-56.0%201220152018202120242025
0.250.50.751-56.0%2016201920222025
Operating margin-69.1%
Net margin-65.4%
Return on assets-43.3%

Each USD of equity lost 56 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
−0.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.4%
−0.0%
+33.9%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.020.00201220152018202120242025
0.010.002016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 20.3M
total assets, end of FY2025
Total assetsUSD 20.3M
EquityUSD 16.3M
CashUSD 3.6M
Current ratio6.00×

Equity funds 80% of total assets.

History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−13.06
−10971.40
−291.52
−15.15
−2.23
−0.11
−0.42
−0.29
−0.70
−2.24
−4.82
−0.31
−0.07
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−56.0
−76.7
−85.4
−29.1
−65.5
−36.1
−109.9
−41.9
−75.3
−689.3
−723.1
−1565.7
·
·
Shares out B
0.00
0.00
0.00
0.00
0.01
0.00
0.03
0.03
0.02
0.01
0.00
0.02
0.02
0.02

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
55 of 55
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed